ImmunityBio, Inc. (IBRX)
Market Open
21 Jul, 17:23
$
8. 04
+0.54
+7.2048%
$
7.85B Market Cap
- P/E Ratio
- Div Yield
5M Volume
-0.93 Eps
$ 7.5
Previous Close 
Want to track IBRX and more in your Portfolio? 🎯
Sign up for Marketlog, a portfolio tracker that will exceed your expectations!
ImmunityBio: Anktiva's Launch Demands A Reassessment
ImmunityBio's flagship product, Anktiva, has been launched in the market for the treatment of bladder cancer, with strong clinical data supporting its efficacy. The company is well-prepared for the launch, with a strong sales force, established distribution channels, and sufficient inventory. Analyst projections suggest significant growth for ImmunityBio, with the potential for Anktiva to become a blockbuster drug and drive the company's revenue in the coming years.
Seekingalpha | 2 years ago
